April 28, 2020 / 1:12 AM / a month ago

BRIEF-Pharmaxis Says Bone Cancer Drug To Commence Phase 2 Studies In Q4

April 28 (Reuters) - Pharmaxis Ltd:

* PXS CANCER DRUG READY TO COMMENCE PHASE 2 STUDIES Q4 2020

* PROGRESSING TO PHASE 2 STUDY OF ORAL ANTI‐FIBROTIC PAN‐LYSYL OXIDASE INHIBITOR TO TREAT MYELOFIBROSIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below